Cooley Advises on Follow-On Offerings for Reata + argenx

New York – December 5, 2019 – In separate transactions that closed within a week of each other, Cooley advised on follow-on offerings for Reata Pharmaceuticals and argenx that total more than $1 billion.

Reata closed its $505 million follow-on offering of 2,760,000 shares of Class A common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. Cooley partners Rich Segal, Div Gupta and Charlie Kim led the team advising the underwriters. Citigroup, Jefferies, SVB Leerink and Stifel acted as the joint book-running managers for the offering. Cantor, Baird and Ladenburg Thalmann acted as co-managers for the offering.

Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation.

argenx closed its $557 million follow-on offering of 4,600,000 ordinary shares, which also includes the full exercise of the underwriters’ option to purchase additional shares. Cooley partners Div Gupta, Rich Segal and Brent Siler led the team advising the underwriters. Morgan Stanley, Cowen, BofA Securities and Evercore acted as joint book-running managers for the offering. Kempen acted as lead manager for the offering and Wolfe Capital Markets and Advisory acted as co-manager.

argenx is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 1,000+ lawyers across 15 offices in the United States, Asia and Europe.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may have been generated with the assistance of artificial intelligence (AI) in accordance with our AI Principles, may be considered Attorney Advertising and is subject to our legal notices.